• SPX
  • $5,959.78
  • 0.19 %
  • $11.07
  • DJI
  • $44,223.17
  • 0.8 %
  • $352.81
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $18,973.79
  • 0.01 %
  • $1.37
Immuneering Corporation (IMRX) Stock Price, News & Analysis

Immuneering Corporation (IMRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.11

-$0

(0%)

Day's range
$2.08
Day's range
$2.25
50-day range
$1.68
Day's range
$3.83
  • Country: US
  • ISIN: US45254E1073
52 wk range
$1
Day's range
$8.89
  • CEO: Dr. Benjamin J. Zeskind M.B.A., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.84
  • Piotroski Score 0.00
  • Grade Buy
  • Symbol (IMRX)
  • Company Immuneering Corporation
  • Price $2.11
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $2.08
  • Day High $2.25
  • Year High $8.89

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/05/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $13.00
  • High Stock Price Target $41.00
  • Low Stock Price Target $3.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.86
  • Trailing P/E Ratio -0.74
  • Forward P/E Ratio -0.74
  • P/E Growth -0.74
  • Net Income $-53,471,622

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Immuneering Corporation Frequently Asked Questions

  • What were the earnings of IMRX in the last quarter?

    In the last quarter Immuneering Corporation earnings were on Wednesday, November, 13th. The Immuneering Corporation maker reported -$0.49 EPS for the quarter, beating analysts' consensus estimates of -$0.54 by $0.05.

  • What is the Immuneering Corporation stock price today?

    Today's price of Immuneering Corporation is $2.11 — it has decreased by 0% in the past 24 hours. Watch Immuneering Corporation stock price performance more closely on the chart.

  • Does Immuneering Corporation release reports?

    Yes, you can track Immuneering Corporation's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Immuneering Corporation stock forecast?

    Watch the Immuneering Corporation chart and read a more detailed Immuneering Corporation stock forecast to see what analysts suggest you do with its shares.

  • What is Immuneering Corporation stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Immuneering Corporation stock ticker.

  • How to buy Immuneering Corporation stocks?

    Like other stocks, IMRX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Immuneering Corporation's EBITDA?

    Immuneering Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Immuneering Corporation’s financial statements.

  • What is the Immuneering Corporation's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Immuneering Corporation stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Immuneering Corporation's financials relevant news, and technical analysis. Immuneering Corporation's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Immuneering Corporation stock currently indicates a “sell” signal. For more insights, review Immuneering Corporation’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.